5:37 PM
 | 
May 06, 2010
 |  BC Extra  |  Company News

Aldagen discontinues ALD-101, amends IPO

Aldagen Inc. (Durham, N.C.) disclosed in an SEC filing that in January it discontinued development of lead clinical candidate ALD-101 to improve cord blood transplantation in pediatric patients with inherited metabolic disorders. The company said the agency was unlikely to accept the use of historical controls from a Phase I trial of ALD-101 as a comparator in...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >